Zenocutuzumab‑zbco Receives FDA Orphan Drug Designation for Treatment of Cholangiocarcinoma
Zenocutuzumab‑zbco received FDA Orphan Drug Designation for treatment of cholangiocarcinoma.
Partner Therapeutics announced that the U.S. Food and Drug Administration granted Orphan Drug Designation to zenocutuzumab‑zbco for adults with advanced unresectable or metastatic cholangiocarcinoma harboring an NRG1 gene fusion.
The orphan designation is a regulatory milestone that can accelerate development, reduce costs, and provide market exclusivity for a treatment of a rare and aggressive cancer with limited therapeutic options and a five‑year survival rate below 15%.
Evidence level: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Related signals
- The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma
- Scientists build cell line atlas of deadly cancers of the bile ducts and gallbladder
- Cholangiocarcinoma Workup: Laboratory Studies, Imaging Studies, Procedures
- New EASL Clinical Practice Guidelines on extrahepatic cholangiocarcinoma
- An open‑label study of pemigatinib in cholangiocarcinoma: final results from FIGHT‑202